08:00 , Jan 7, 2016 |  BC Innovations  |  Translation in Brief

New beginnings

The idea of regenerating tissue in coronary arteries after heart disease or injury has been slow to take hold because, although it's well-established that cells from the epicardium give rise to the smooth muscle in...
07:00 , Jul 23, 2015 |  BC Innovations  |  Tools & Techniques

Gene therapy's coming of age

After more than 20 years of trial and error in gene therapy, the field is taking off with one product approved in Europe, several poised to enter the market in the U.S., a surge of...
07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Taxus Cardium, Shenzhen Qianhai Taxus Insdustry Capital Management deal

Taxus Cardium granted Shenzhen the first right to negotiate for an exclusive license to develop and commercialize three Taxus products in Asian countries. The products include Generx alferminogene tadenovec, an adenoviral vector carrying the fibroblast...
07:00 , May 4, 2015 |  BC Week In Review  |  Company News

Taxus Cardium, Dr. Reddy’s Laboratories Ltd. deal

Taxus granted Dr. Reddy’s exclusive rights to co-develop and commercialize Generx cardionovo alferminogene tadenovec in the Commonwealth of Independent States (CIS), Venezuela, Vietnam and Myanmar. Dr. Reddy’s also has the right of first refusal for...
00:22 , Apr 7, 2015 |  BC Extra  |  Company News

Management tracks

Protein therapeutics company Acceleron Pharma Inc. (NASDAQ:XLRN) named Francois Nader chairman. Nader joined the company's board in December. He was CEO and director of NPS Pharmaceuticals Inc. , which was acquired by Shire plc (LSE:SHP;...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

Generx cardionovo alferminogene tadenovec: Interim Phase III data

Interim data from 11 patients with myocardial ischemia due to coronary artery disease (CAD) in the open-label, Russian Phase III ASPIRE trial showed that an intracoronary infusion of Generx led to a 24.4% improvement in...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Company News

Taxus Cardium board of directors update

Taxus Cardium Pharmaceuticals Group Inc. (OTCQB:CRXM), San Diego, Calif.   Business: Cardiovascular   Appointed: John Wallace, president of Philadelphia Financial Services LLC; and Jiayue Zhang, president and chairman of Shanxi Taxus Pharmaceuticals Co. Ltd.  ...
07:00 , Apr 7, 2014 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Small but mighty

Despite a correction at the end of March, all biotech market cap segments finished the first quarter in positive territory. Microcaps set the pace with a 10% gain, while large caps added 7% and were...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Shanxi Taxus, Taxus Cardium deal

Cardium Therapeutics Inc. changed its name to Taxus Cardium and partnered with Shanxi Taxus to promote each other's products. Under the deal, Shanxi Taxus agreed to apply "commercially reasonable efforts" to assist Taxus Cardium to...
08:00 , Mar 6, 2014 |  BC Innovations  |  Targets & Mechanisms

Heart cells: no longer undivided

The inability of adult heart cells to divide rapidly enough to repair cardiac damage has been a major impediment to regenerating heart tissue and preventing fibrosis after myocardial infarction. Now, a U.S. team has used...